Anika Therapeutics ANIK Operating lease right-of-use assets amortization expense
Operating lease right-of-use assets amortization expense at other companies
Other financials
Where this comes from
Reported directly by Anika Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Anika Therapeutics's operating lease right-of-use assets amortization expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Anika Therapeutics's operating lease right-of-use assets amortization expense?
- Anika Therapeutics (ANIK) reported operating lease right-of-use assets amortization expense of $465K in Q2 2026.
- How has Anika Therapeutics's operating lease right-of-use assets amortization expense changed year-over-year?
- Anika Therapeutics's operating lease right-of-use assets amortization expense decreased by 5.1% year-over-year, from $490K to $465K.
- What is the long-term trend for Anika Therapeutics's operating lease right-of-use assets amortization expense?
- Over 4 years (2021 to 2025), Anika Therapeutics's operating lease right-of-use assets amortization expense has grown at a 4.8% compound annual growth rate (CAGR), from $1.71M to $2.06M.